Kronos Bio (KRON)
(Delayed Data from NSDQ)
$0.76 USD
-0.21 (-22.09%)
Updated May 24, 2024 03:59 PM ET
After-Market: $0.78 +0.02 (3.22%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth A Momentum D VGM
Price, Consensus and EPS Surprise
KRON 0.76 -0.21(-22.09%)
Will KRON be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for KRON based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for KRON
Down -5.63% in 4 Weeks, Here's Why Kronos Bio (KRON) Looks Ripe for a Turnaround
Kronos Bio, Inc. (KRON) Reports Q1 Loss, Tops Revenue Estimates
KRON: What are Zacks experts saying now?
Zacks Private Portfolio Services
Travere Therapeutics (TVTX) Reports Q1 Loss, Misses Revenue Estimates
Kronos Bio (KRON) Upgraded to Buy: What Does It Mean for the Stock?
Kronos Bio, Inc. (KRON) Reports Q3 Loss, Lags Revenue Estimates
Other News for KRON
Why NetEase Shares Are Trading Lower? Here Are Other Stocks Moving In Friday's Mid-Day Session
Kronos Bio to Present Clinical Update on Phase 1/2 Trial of KB-0742 at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
Kronos Bio to Participate in Three Upcoming Healthcare Conferences and Events
Kronos Bio Appoints Deborah Knobelman, Ph.D. as Chief Operating Officer and Chief Financial OfficerÂ
Kronos Bio appoints Knobelman as CFO and COO